RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Shanghai Ankon Technologies raised $100 million in venture capital to market NaviCam, a swallow-able device about the size of a pill, for imaging the gastric track to diagnose stomach cancer and other gastric problems. The 15-minute minimally-invasive procedure provides doctors with an inside look of a patient’s gastric track. Ankon wants to expand into new markets and develop similar systems for early diagnosis of other diseases. The round included investors SBCVC, Dazhong Investment, Youshi Capital and Tongsheng Capital.
Source: ChinaBio Today
